Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAART

European Journal of Clinical Pharmacology

Volumn 65, Issue 7, 2009, Pages 667-678

  Bertrand, Julie ^a   Treluyer, Jean Marc ^b,c   Panhard, Xavière ^d,e   Tran, Agnes ^c   Auleley, Solange ^a   Rey, Elisabeth ^d   Salmon Céron, Dominique ^c   Duval, Xavier ^c,e   Mentré, France ^d,e  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Institut Cochin   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e BICHAT HOSPITAL   (France)

Author keywords

CYP3A4; Efficacy; Nonlinear mixed effects modeling; Pharmacokinetics; Protease inhibitors; Safety

Indexed keywords

CYTOCHROME P450 3A4; INDINAVIR; RITONAVIR; TRIACYLGLYCEROL; VIRUS RNA;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER PROGRAM; CONTROLLED STUDY; DIARRHEA; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MAXIMUM PLASMA CONCENTRATION; NEPHROLITHIASIS; PATIENT COMPLIANCE; POPULATION RESEARCH; PRIORITY JOURNAL; SHORT COURSE THERAPY; STOCHASTIC MODEL; TREATMENT RESPONSE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; AREA UNDER CURVE; CLINICAL TRIALS AS TOPIC; COHORT STUDIES; CYTOCHROME P-450 CYP3A; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, STATISTICAL; MULTICENTER STUDIES AS TOPIC; PHARMACOGENETICS; PILOT PROJECTS; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 67649126219     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-009-0660-5     Document Type: Article

References (52)

1. C Solas A Lafeuillade P Halfon 2003 Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients Antimicrob Agents Chemother 47 238 243 (Pubitemid 36070370)
2. S Letendre J Marquie-Beck E Capparelli 2008 Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system Arch Neurol 65 65 70
3. F Collin G Chêne S Retout G Peytavin D Salmon E Bouvet F Raffi R Garraffo F Mentré X Duval ANRS CO8 Aproco-Copilote Study Group 2007 Indinavir trough concentration as a determinant of early nephrolithiasis in HIV-1-infected adults Ther Drug Monit 29 164 170 (Pubitemid 46716181)
4. C Flexner 1998 HIV-protease inhibitors N Engl J Med 338 1281 1292 (Pubitemid 28216584)
5. LL Von Moltke DJ Greenblatt JM Grassi 1998 Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir J Clin Pharmacol 38 106 111 (Pubitemid 28117365)
6. A Hsu GR Granneman RJ Bertz 1998 Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents Clin Pharmacokinet 35 275 291 (Pubitemid 28491214)
7. V Soriano P Garcya-Gasco E Vispo A Ruiz-Sancho F Blanco L Martyn-Carbonero S Rodryguez-Novoa J Morello C de Mendoza P Rivas P Barreiro J Gonzalez-Lahoz 2008 Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial J Antimicrob Chemother 61 200 205
8. Collot-Teixeira S, De Lorenzo F, Waters L, Fletcher C, Back D, Mandalia S, Pozniak A, Yilmaz S, McGregor JL, Gazzard B, Boffito M (2009) Impact of different low-dose ritonavir regimens on lipids, CD36, and adipophilin expression. Clin Pharmacol Ther 85(4):375-378
9. Csajka C, Marzolini C, Fattinger K et al (2004) Population pharmacokinetics of indinavir in patients infected with human immunodeficiency virus. Antimicrob Agents Chemother 48:3226-32
10. K Brendel M Legrand A Taburet 2005 Population pharmacokinetic analysis of indinavir in hiv-infected patient treated with a stable antiretroviral therapy Fundam Clin Pharmacol 19 373 383 (Pubitemid 40769459)
11. BS Kappelhoff ADR Huitema SUC Sankatsing 2005 Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients Br J Clin Pharmacol 60 276 286 (Pubitemid 41224135)
12. C Solas N Simon MP Drogoul 2007 Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients Br J Clin Pharmacol 64 353 362 (Pubitemid 47283866)
13. C Verstuyft F Marcellin L Morand-Joubert 2005 Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy AIDS 19 2127 2131 (Pubitemid 41669001)
14. PL Anderson J Lamba CL Aquilante 2006 Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study J Acquir Immune Defic Syndr 42 441 449 (Pubitemid 44050891)
15. JK Lamba YS Lin EG Schuetz 2002 Genetic contribution to variable human CYP3A-mediated metabolism Adv Drug Deliver Rev 54 1271 1294 (Pubitemid 35284253)
16. M Lichterfeld HD Nischalke F Bergmann 2002 Long-term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy HIV Med 3 37 43 (Pubitemid 34189594)
17. X Duval F Mentre C Lamotte 2005 Indinavir plasma concentration and adherence score are codeterminant of early virologic response in HIV-infected patients of the APROCO cohort Ther Drug Monit 27 63 70 (Pubitemid 40189976)
18. JP Dieleman IC Gyssens ME van der Ende 1999 Urological complaints in relation to indinavir plasma concentrations in HIV-infected patients AIDS 13 473 478
19. Duval X, Mentré F, Rey E et al (2009) Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART regimen-ANRS 111 trial. Fundam Clin Pharmacol (in press)
20. D Hirt F Mentré A Tran 2008 Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patients Br J Clin Pharmacol 65 548 557
21. P Carrieri V Cailleton V Le Moing 2001 The dynamic of adherence to highly active antiretroviral therapy: results from the french national APROCO Cohort J Acq Immun Def Synd 28 232 239 (Pubitemid 33055448)
22. I Cascorbi T Gerloff A Johne 2001 Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects Clin Pharmacol Ther 69 169 174 (Pubitemid 32225417)
23. H Dally L Edler B Jager 2003 The CYP3A4*1B allele increases risk for small cell lung cancer: effect of gender and smoking dose Pharmacogenetics 13 607 618 (Pubitemid 37311147)
24. J Crow 1999 Hardy, Weinberg and language impediments Genetics 152 821 825 (Pubitemid 29330885)
25. J Pritchard M Stephens P Donnelly 2000 Inference of population structure using multilocus genotype data Genetics 155 945 959 (Pubitemid 30397141)
26. E Kuhn M Lavielle 2005 Maximum likelihood estimation in nonlinear mixed effects models Comput Stat Data Anal 49 1020 1038
27. M Lavielle 2008 MONOLIX (MOdèles NOn LInéaires à effets miXtes) MONOLIX group Orsay, France http://software.monolix.org/index.php Lavielle M (2008) MONOLIX (MOdèles NOn LInéaires à effets miXtes). MONOLIX group, Orsay, France. Available at: http://software.monolix. org/index.php
28. M Lavielle F Mentré 2007 Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software J Pharmacokinet Pharmacodyn 34 229 249 (Pubitemid 46536259)
29. Gelman A, Carlin JB, Stern HS et al (1995) Bayesian data analysis. Chapman & Hall, London
30. J Bertrand E Comets F Mentré 2008 Comparison of model-based tests and selection strategies to detect genetic polymorphisms influencing pharmacokinetic parameters J Biopharm Stat 18 1084 1102
31. Manly B (1998) Randomization. bootstrap and Monte Carlo methods in biology. Chapman & Hall, London
32. C Goujard M Legrand X Panhard 2005 High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on highly active antiretroviral therapy Clin Pharmacokinet 44 1267 1278 (Pubitemid 41832567)
33. U Fuhr A Jetter J Kirchheiner 2007 Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach Clin Pharmacol Ther 81 270 283 (Pubitemid 46174825)
34. T Ikezoe Y Hisatake T Takeuchi 2004 HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo Cancer Res 64 7426 7431 (Pubitemid 39372084)
35. S Zhou S Yung Chan B Cher Goh 2005 Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs Clin Pharmacokinet 44 279 304 (Pubitemid 40477790)
36. M Rittweger K Arastéh 2007 Clinical pharmacokinetics of darunavir Clin Pharmacokinet 46 739 756 (Pubitemid 47347446)
37. A Spurdle B Goodwin E Hodgson 2002 The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer Pharmacogenetics 12 355 366 (Pubitemid 34816415)
38. P He MH Court DJ Greenblatt 2005 Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo Clin Pharmacol Ther 77 373 387 (Pubitemid 40719266)
39. DA Hesselink RH van Schaik IP van der Heiden 2003 Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus Clin Pharmacol Ther 74 245 254 (Pubitemid 37083100)
40. A Tran V Jullien J Alexandre 2006 Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms Clin Pharmacol Ther 79 570 580 (Pubitemid 43833447)
41. B Amirimani B Ning AC Deitz 2003 Increased transcriptional activity of the CYP3A4*1B promoter variant Environ Mol Mutagen 42 299 305 (Pubitemid 38054375)
42. K Yeh J Stone A Carides 1999 Simultaneous investigation of indinavir nonlinear pharmacokinetics and bioavailability in healthy volunteers using stable isotope labeling technique: study design and model-independent data analysis J Pharm Sci 88 568 573 (Pubitemid 29220986)
43. Lu JF, Blaschke TF, Flexner C et al. (2002) Model-based analysis of the pharmacokinetic interactions between ritonavir, nelfinavir and saquinavir after simultaneous and staggered oral administration. Drug Metab Dispos 30:1455-1461 (Pubitemid 35397054)
44. BS Kappelhoff ADR Huitema KML Crommentuyn 2005 Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients Br J Clin Pharmacol 59 174 182 (Pubitemid 40208853)
45. A Schön M del Mar Ingaramo E Freire 2003 The binding of HIV-1 protease inhibitors to human serum proteins Biophys Chem 105 221 230 (Pubitemid 37123062)
46. K Jones PG Hoggard S Khoo 2001 Effect of alpha1-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir in vitro Br J Clin Pharmacol 51 99 102 (Pubitemid 32118826)
47. X Zhang R Schooley J Gerber 1999 The effect of increasing alpha1-acid glycoprotein concentration on the antiviral efficacy of human immunodeficiency virus protease inhibitors J Infect Dis 180 1833 1837
48. A Samson M Lavielle F Mentré 2006 Extension of the SAEM algorithm to left-censored data in nonlinear mixed-effects model: Application to HIV dynamics model Comput Stat Data Anal 51 1562 1574 (Pubitemid 44709222)
49. CV Fletcher 1999 Pharmacologic considerations for therapeutic success with antiretroviral agents Ann Pharmacother 33 989 995 (Pubitemid 29420998)
50. DM Burger PWH Hugen RE Aarnoutse 2001 A retrospective, cohort-based survey of patients using twice-daily indinavir+ritonavir combinations: pharmacokinetics, safety and efficacy J Acquir Immune Defic Syndr 26 218 224 (Pubitemid 32246551)
51. CR Rayner KJ Galbraith JL Marriott 2002 A critical evaluation of the therapeutic range of indinavir Ann Pharmacother 36 1230 1237 (Pubitemid 34755802)
52. G Behrens A Dejam H Schmidt 1999 Impaired glucose tolerance, beta cell function, and lipid metabolism: HIV patients under treatment with protease inhibitors AIDS 13 F63 F70